BOXED O
WARNING O
: O
WARNING O
: O
CARDIOMYOPATHY O
and O
INFUSION-RELATED O
REACTIONS O
WARNING O
: O
CARDIOMYOPATHY O
and O
INFUSION-RELATED O
REACTIONS O
* O
DOXIL O
( O
doxorubicin O
HCl O
liposome O
injection O
) O
can O
cause O
myocardial B-OSE_Labeled_AE
damage I-OSE_Labeled_AE
, O
including O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
as O
the O
total O
cumulative O
dose O
of O
doxorubicin O
HCl O
approaches O
550 O
mg/m2 O
. O

In O
a O
clinical O
study O
of O
250 O
patients O
with O
advanced O
cancer B-Not_AE_Candidate
who O
were O
treated O
with O
DOXIL O
, O
the O
risk O
of O
cardiotoxicity B-OSE_Labeled_AE
was O
11 O
% O
when O
the O
cumulative O
anthracycline O
dose O
was O
between O
450-550 O
mg/m2 O
. O

Prior O
use O
of O
other O
anthracyclines O
or O
anthracenediones O
should O
be O
included O
in O
calculations O
of O
total O
cumulative O
dosage O
. O

The O
risk O
of O
cardiomyopathy B-OSE_Labeled_AE
may O
be O
increased O
at O
lower O
cumulative O
doses O
in O
patients O
with O
prior O
mediastinal O
irradiation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Acute B-OSE_Labeled_AE
infusion I-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
consisting O
of O
, O
but O
not O
limited O
to O
, O
flushing B-OSE_Labeled_AE
, O
shortness B-OSE_Labeled_AE
of I-OSE_Labeled_AE
breath I-OSE_Labeled_AE
, O
facial B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
tightness B-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
chest O
or O
throat I-OSE_Labeled_AE
, O
and/or O
hypotension B-OSE_Labeled_AE
occurred O
in O
11 O
% O
of O
patients O
with O
solid B-Not_AE_Candidate
tumors I-Not_AE_Candidate
treated O
with O
DOXIL O
. O

Serious O
, O
life-threatening O
and O
fatal B-NonOSE_AE
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
[ O
see O
Dosage O
and O
Administration O
( O
2.6 O
) O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
CARDIOMYOPATHY O
and O
INFUSION-RELATED O
REACTIONS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Myocardial O
damage O
may O
lead O
to O
congestive O
heart O
failure O
and O
may O
occur O
as O
the O
total O
cumulative O
dose O
of O
doxorubicin O
HCl O
approaches O
550 O
mg/m2 O
. O

The O
risk O
of O
cardiomyopathy O
may O
be O
increased O
at O
lower O
cumulative O
doses O
with O
mediastinal O
irradiation O
( O
5.1 O
) O
. O

* O
Acute O
infusion-related O
reactions O
occurred O
in O
11 O
% O
of O
patients O
with O
solid O
tumors O
. O

Serious O
, O
life-threatening O
, O
and O
fatal O
infusion O
reactions O
have O
been O
reported O
. O

Medications/emergency O
equipment O
to O
treat O
such O
reactions O
should O
be O
available O
for O
immediate O
use O
( O
5.2 O
) O
. O

